S
Scott W. Andersen
Researcher at Eli Lilly and Company
Publications - 62
Citations - 3032
Scott W. Andersen is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Olanzapine & Solanezumab. The author has an hindex of 19, co-authored 59 publications receiving 2288 citations.
Papers
More filters
Journal ArticleDOI
Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.
Pierre V. Tran,S.H. Hamilton,Amy J. Kuntz,Janet H. Potvin,Scott W. Andersen,Charles Jr Beasley,Gary D. Tollefson +6 more
TL;DR: Olanzapine seemed to have a risk-versus-benefit advantage in the management of psychotic symptoms, and the differential preclinical profiles of these two drugs were also evident in a controlled, clinical investigation.
Journal ArticleDOI
Donanemab in Early Alzheimer's Disease.
Mark A Mintun,Albert C. Lo,Cynthia Duggan Evans,Alette M. Wessels,Paul A. Ardayfio,Scott W. Andersen,Sergey Shcherbinin,JonDavid Sparks,John R. Sims,Miroslaw Brys,Liana G. Apostolova,Stephen Salloway,Daniel Skovronsky +12 more
TL;DR: In this paper, an antibody that targets a modified form of deposited amyloid-β (Aβ) peptide is investigated for Alzheimer's disease, which is a hallmark of Alzheimer's.
Journal ArticleDOI
Olanzapine versus placebo in the treatment of acute mania
Mauricio Tohen,Todd M. Sanger,Susan L. McElroy,G.D. Tollefson,S. L. Grundy,M. Greaney,T. Jacobs,S.R. David,Scott W. Andersen,V. Toma +9 more
TL;DR: The results from this study suggest that compared with placebo, olanzapine has superior efficacy for the symptoms of acute mania.
Journal ArticleDOI
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
Stephen Salloway,Martin R. Farlow,Eric McDade,David B. Clifford,Guoqiao Wang,Jorge J. Llibre-Guerra,Janice M. Hitchcock,Susan Mills,Anna Santacruz,Andrew J. Aschenbrenner,Jason Hassenstab,Tammie L.S. Benzinger,Brian A. Gordon,Anne M. Fagan,Kelley Coalier,Carlos Cruchaga,Alison Goate,Richard J. Perrin,Chengjie Xiong,Yan Li,John C. Morris,B. Joy Snider,Catherine J. Mummery,G. Mustafa Surti,Didier Hannequin,David Wallon,Sarah B. Berman,James J. Lah,Ivonne Z. Jimenez-Velazquez,Erik D. Roberson,Christopher H. van Dyck,Lawrence S. Honig,Raquel Sánchez-Valle,William S. Brooks,Serge Gauthier,Douglas Galasko,Colin L. Masters,Jared R. Brosch,Ging-Yuek Robin Hsiung,Suman Jayadev,Maïté Formaglio,Mario Masellis,Roger Clarnette,J. Pariente,Bruno Dubois,Florence Pasquier,Clifford R. Jack,Robert A. Koeppe,Peter J. Snyder,Paul S. Aisen,Ronald G. Thomas,Scott M. Berry,Barbara A. Wendelberger,Scott W. Andersen,Karen C. Holdridge,Mark A. Mintun,Roy Yaari,John R. Sims,Monika Baudler,Paul Delmar,Rachelle S. Doody,Paulo Fontoura,Caroline Giacobino,Geoffrey A. Kerchner,Randall J. Bateman +64 more
TL;DR: A randomized, placebo-controlled, multi-arm trial of gantenerumab or solanezumab in participants with DIAD across asymptomatic and symptomatic disease stages was conducted in this paper.
Journal ArticleDOI
A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features
Anthony J. Rothschild,Douglas J. Williamson,Mauricio Tohen,Alan F. Schatzberg,Scott W. Andersen,Luann E. Van Campen,Todd M. Sanger,Gary D. Tollefson +7 more
TL;DR: Patients with major depression with psychotic features treated with OLZ monotherapy did not demonstrate significant depressive symptom improvement compared with placebo in either trial; however, an olanzapine/fluoxetine combination was associated with significant improvement comparedwith placebo in one trial and was well tolerated.